For sales

📢Highlights from the Week of 02 February 2026 – 09 February 2026 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 02 February 2026 - 09 February 2026 ( FDA, Approval ) FDA approves Exelixis' zanzalintinib in combination with atezolizumab for the treatment of adult patients with previously treated metastatic colorectal cancer, with a PDUFA date of December 3, 2026 ( EU, Approval ) The European Commission approves GSK's NUCALA as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease based on the data from Phase III MATINEE trial ( NMPA, Approval ) NMPA approves Bayer's NUBEQA in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer based on the Phase III ARANOTE trial ( NMPA, Approval ) NMPA approves a new indication of Kelun-Biotech's sacituzumab tirumotecan to treat unresectable or metastatic HR+/HER2- breast cancer who previously received endocrine therapy and at least one line of chemotherapy Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.